Q2 FY2026 EarningsQ2 FY2026 results missed consensus estimates on both top and bottom lines. Revenue of $1.4M fell significantly short of the $12.3M expectation due to the wind-down of legacy collaboration obligations. GAAP EPS of -$0.09 missed the -$0.08 mean estimate as R&D spending intensified to $17.6M to support the Varseta-M program. Despite the financial miss, the expansion of the Regeneron alliance and a strong cash position of $330.3M (runway into 2H 2028) provide a robust clinical development buffer.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Cytomx Therap(CTMX) the Revenue is 1.418 M (-92.4%), Miss estimate;the EBIT is -23.78 M (-1749%), Miss estimate;the EPS is -0.09 (--%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.00B92.40%
0.01B33.86%
-0.01B58.54%
EBITMiss expectations
-0.02B1749.22%
-0.02B1320.19%
-0.01B429.03%
EPSMiss expectations
-0.09--
-0.0812--
-0.0088--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf